By Fineline Cube 
Innovent Biologics (HKG: 1801) announced that its independently developed Daboxin (ipilimumab N01) has received marketing approval from the drug regulatory authority of the Macau Special Administrative Region of China for use in combination with Tyvyt (sintilimab) as a neoadjuvant therapy for patients with resectable stage IIB–III microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colon cancer.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | Macau SAR Drug Regulatory Authority |
| Approval Type | Marketing approval |
| Products | Daboxin (ipilimumab N01) + Tyvyt (sintilimab) |
| Indication | Neoadjuvant therapy for resectable stage IIB–III MSI-H/dMMR colon cancer |
| Treatment Setting | Pre-surgical (neoadjuvant) |
| Announcement Date | 15 Jul 2026 |
Drug Profile & Development Partnership
- Daboxin (ipilimumab N01): Recombinant fully human anti-CTLA-4 monoclonal antibody independently developed by Innovent Biologics
- Tyvyt (sintilimab): PD-1 inhibitor co-developed by Innovent Biologics and Eli Lilly
- Regimen: “Dual-immunotherapy” combining CTLA-4 and PD-1 inhibition
- Intellectual Property: Fully owned by Innovent Biologics (ipilimumab N01) with co-development rights (sintilimab)
Clinical Evidence – NeoShot-III Phase 3 Trial
| Endpoint | Dual-Immunotherapy Group | Upfront Surgery Group | Clinical Impact |
|---|---|---|---|
| Pathological Complete Response (pCR) | 82% (41/50 patients) | Not applicable | Exceptional tumor eradication pre-surgery |
| Postoperative Adjuvant Chemotherapy | 1.6% (1/62 patients) | 21.3% (13/61 patients) | 92% reduction in need for additional chemotherapy |
| Safety Profile | Favorable, no significant additional safety risks | Standard surgical outcomes | Comparable safety to upfront surgery approach |
The NeoShot-III study demonstrated that neoadjuvant dual-immunotherapy not only achieved remarkable pathological complete response rates but also dramatically reduced the need for postoperative adjuvant chemotherapy, representing a paradigm shift in colon cancer treatment.
Market Impact & Therapeutic Innovation
- MSI-H/dMMR Colon Cancer: Represents approximately 15% of all colon cancer cases with high unmet need for effective neoadjuvant approaches
- Competitive Edge: First approved dual-immunotherapy neoadjuvant regimen specifically for MSI-H/dMMR colon cancer in Greater China region
- Strategic Positioning: Establishes Innovent Biologics as a leader in immuno-oncology combinations with potential for global expansion beyond Macau approval
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the commercial launch and market adoption of the dual-immunotherapy regimen. Actual results may differ due to risks including market penetration, competitive dynamics, and potential regulatory expansions.-Fineline Info & Tech